SlideShare une entreprise Scribd logo
1  sur  20
The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
References/Data Source ,[object Object],[object Object],[object Object],[object Object]
Table of Contents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Orphan Drug Act ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Provisions of the Orphan Drug Act: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Governmental Entities Implementing the Orphan Drug Act ,[object Object],[object Object],[object Object]
Has the Orphan Drug Act Met It’s Objectives? ,[object Object],[object Object],[object Object],[object Object]
Findings: ,[object Object],[object Object],[object Object],[object Object]
Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
Findings: ,[object Object],[object Object],[object Object],[object Object]
Conclusion: ,[object Object],[object Object],[object Object]
What Does This Mean To You?: Managed Care Vision Today & Beyond ,[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object]

Contenu connexe

Tendances

Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDr. Vishal Pawar
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.Audumbar Mali
 
IND INDA ANDA Application
IND INDA ANDA ApplicationIND INDA ANDA Application
IND INDA ANDA ApplicationRoshan Bodhe
 
Regulatory requirements for otc drugs as per usfda
Regulatory requirements for otc drugs as per usfdaRegulatory requirements for otc drugs as per usfda
Regulatory requirements for otc drugs as per usfdaKhushboo Bhatia
 
Comparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTCComparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTCGuru Balaji .S
 
Clinical Trial Phase 3 And 4
Clinical Trial Phase 3 And 4Clinical Trial Phase 3 And 4
Clinical Trial Phase 3 And 4Sanchit Rastogi
 
Fda med watch
Fda med watchFda med watch
Fda med watchSridhar S
 
Orphan drugs presentation
Orphan drugs presentationOrphan drugs presentation
Orphan drugs presentationAtul Rajpara
 
PMS (post marketing surveillance)
PMS (post marketing surveillance)PMS (post marketing surveillance)
PMS (post marketing surveillance)SANDEEP LOHMOR
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Aakashdeep Raval
 
Abbreviated new drug application submission
Abbreviated new drug application submissionAbbreviated new drug application submission
Abbreviated new drug application submissionGaurav Sharma
 
pharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONpharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONgarimasaini33
 

Tendances (20)

Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan Drugs
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.
 
IND INDA ANDA Application
IND INDA ANDA ApplicationIND INDA ANDA Application
IND INDA ANDA Application
 
Regulatory requirements for otc drugs as per usfda
Regulatory requirements for otc drugs as per usfdaRegulatory requirements for otc drugs as per usfda
Regulatory requirements for otc drugs as per usfda
 
Comparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTCComparasion of IND,NDA,BLA,ANDA,OTC
Comparasion of IND,NDA,BLA,ANDA,OTC
 
Clinical Trial Phase 3 And 4
Clinical Trial Phase 3 And 4Clinical Trial Phase 3 And 4
Clinical Trial Phase 3 And 4
 
Fda med watch
Fda med watchFda med watch
Fda med watch
 
What is an orphan drug?
What is an orphan drug?What is an orphan drug?
What is an orphan drug?
 
Orphan drugs presentation
Orphan drugs presentationOrphan drugs presentation
Orphan drugs presentation
 
PMS (post marketing surveillance)
PMS (post marketing surveillance)PMS (post marketing surveillance)
PMS (post marketing surveillance)
 
Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.Preparation of Clinical Trial Protocol of India.
Preparation of Clinical Trial Protocol of India.
 
GVP module VI
GVP module VIGVP module VI
GVP module VI
 
New drug application
New drug applicationNew drug application
New drug application
 
Abbreviated new drug application submission
Abbreviated new drug application submissionAbbreviated new drug application submission
Abbreviated new drug application submission
 
pharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONpharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNION
 
Orphan drugs
Orphan drugsOrphan drugs
Orphan drugs
 
CLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOLCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL
 
Orphan drugs
Orphan drugsOrphan drugs
Orphan drugs
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 

Similaire à The Orphan Drug Act

The science of hope
The science of hopeThe science of hope
The science of hopeFreedom Monk
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesKuldeep Badoniya
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan DrugsBill Smith
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug ReportBill Smith
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Harsha Rajasimha
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.docsuprajakotam
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Office of Health Economics
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigmsjalisman
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010HealthlinkWorldwide
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environmentspmaugeri
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...Dr Aneek Gupta
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...MedicineAndHealthUSA
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneAmerica's Health Insurance Plans
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2bahlinnm
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPMauro Placchi
 
RF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRichard Phillips
 

Similaire à The Orphan Drug Act (20)

The science of hope
The science of hopeThe science of hope
The science of hope
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research Incentives
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan Drugs
 
MMHA 6135 WK 5 App
MMHA 6135 WK 5 AppMMHA 6135 WK 5 App
MMHA 6135 WK 5 App
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.doc
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharma
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigms
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010
 
Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?
 
Twillman preventing rx abuse
Twillman preventing rx abuseTwillman preventing rx abuse
Twillman preventing rx abuse
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environments
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMP
 
RF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology AssessmentRF 2016 07 Health Technology Assessment
RF 2016 07 Health Technology Assessment
 

The Orphan Drug Act

  • 1. The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.